The Ongoing Evolution of COVID-19

Since its emergence in late 2019, SARS-CoV-2 has continuously evolved, giving rise to multiple variants that differ in transmissibility, immune escape, and diagnostic detectability. Understanding these variants is crucial for adapting testing strategies and maintaining public health safety.

WHO Variant Classifications

The World Health Organization (WHO) classifies SARS-CoV-2 variants into three main categories:
• Variants of Concern (VOC): Higher transmissibility, disease severity, or immune escape (e.g., Delta, Omicron)
• Variants of Interest (VOI): Genetic changes predicted to affect virus traits but requiring more study (e.g., Mu, Lambda)
• Variants Under Monitoring (VUM): Emerging strains with early evidence of significance but limited data

Key Variants and Their Impact

1. Delta Variant (B.1.617.2)
• First identified: India, late 2020
• Key traits:
• 60% more transmissible than Alpha
• Higher viral loads leading to faster spread
• Reduced vaccine efficacy against infection but strong protection against severe disease

2. Omicron and Its Subvariants (BA.1 → BA.5 → XBB, Kraken, Arcturus)
• First identified: South Africa, November 2021
• Key traits:
• Significant spike protein mutations → increased immune escape
• Milder disease on average but higher reinfection rates
• Subvariants like XBB.1.5 (Kraken) dominate due to enhanced transmissibility and partial vaccine escape

3. Emerging Variants (e.g., Mu, Lambda)
• Limited circulation globally but monitored closely for immune evasion potential and diagnostic challenges

Diagnostic Challenges

COVID-19 diagnostics have been tested by variant-driven mutations. Spike protein-based tests can lose sensitivity as the virus evolves.

However, GBC’s GB COVID-19 Ag Rapid Test was designed to target the nucleocapsid (N) protein, which remains far more stable than spike proteins.
• Maintains high sensitivity and specificity across major variants
• Provides fast results in 15 minutes
• Widely validated in clinical and regulatory studies

GBC’s Commitment to Accurate Diagnostics

As the virus evolves, GBC continues to:
• Validate performance against emerging variants
• Invest in next-gen testing technologies
• Collaborate with global research partners to ensure testing reliability under changing conditions

Looking Ahead

With SARS-CoV-2 expected to coexist with humanity long-term, rapid and reliable testing will remain critical. GBC is committed to empowering clinicians and individuals alike with accurate diagnostics that adapt to the virus’s evolution.